Authors:
Arévalos, Victor, Ortega Paz, Luis, Fernandez Rodríguez, Diego, Jiménez Díaz, Víctor Alfonso, Bañeras Rius, Jordi, Campo, Gianluca, Rodríguez Santamarta, Miguel, Pérez de Prado, Armando, Gómez Menchero, Antonio, Díaz Fernández, José Franc (...)
Arévalos, Victor, Ortega Paz, Luis, Fernandez Rodríguez, Diego, Jiménez Díaz, Víctor Alfonso, Bañeras Rius, Jordi, Campo, Gianluca, Rodríguez Santamarta, Miguel, Pérez de Prado, Armando, Gómez Menchero, Antonio, Díaz Fernández, José Francisco, Scardino, Claudia, Gonzalo, Nieves, Pernigotti, Alberto, Alfonso, Fernando, Jesús Amat-santos, Ignacio, Silvestro, Antonio, Ielasi, Alfonso, Torre, José María de la, Bastidas, Gabriela, Gómez Lara, Josep, Sabaté, Manel, Brugaletta, Salvatore, CV Covid-19 Registry Investigators
(Read More)
Abstract:
Background Patients presenting with the coronavirus-2019 disease (COVID-19) may have a high risk of cardiovascular adverse events, including death from cardiovascular causes. The long-term cardiovascular outcomes of these patients are entirely unknown. We aim to perform a registry of patients who have undergone a diagnostic nasopharyngeal swab for SARS-CoV-2 and to determine their long-term cardiovascular outcomes. Study and design
Background Patients presenting with the coronavirus-2019 disease (COVID-19) may have a high risk of cardiovascular adverse events, including death from cardiovascular causes. The long-term cardiovascular outcomes of these patients are entirely unknown. We aim to perform a registry of patients who have undergone a diagnostic nasopharyngeal swab for SARS-CoV-2 and to determine their long-term cardiovascular outcomes. Study and design This is a multicenter, observational, retrospective registry to be conducted at 17 centers in Spain and Italy (ClinicalTrials.gov number: NCT04359927). Consecutive patients older than 18 years, who underwent a real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for SARS-CoV2 in the participating institutions, will be included since March 2020, to August 2020. Patients will be classified into two groups, according to the results of the RT-PCR: COVID-19 positive or negative. The primary outcome will be cardiovascular mortality at 1 year. The secondary outcomes will be acute myocardial infarction, stroke, heart failure hospitalization, pulmonary embolism, and serious cardiac arrhythmias, at 1 year. Outcomes will be compared between the two groups. Events will be adjudicated by an independent clinical event committee. Conclusion The results of this registry will contribute to a better understanding of the long-term cardiovascular implications of the COVID19.
(Read More)